Regulatory – Smoke Master

Is the UK’s Latest Regulatory Shake-Up Leaning Towards Harm Reduction or Over-Regulation?

admin — Wed, 05 Aug 2026 03:43:20 +0000

Britain’s vaping sector is entering its most challenging period since e-cigarettes first emerged as a smoking alternative. New taxes, stricter product rules, tighter marketing restrictions and proposals targeting specialist vape retailers are converging at a time when around 5.5 million adults in Great Britain use vaping products, most of them former or current smokers.

For tobacco harm reduction advocates, the central question is no longer whether vaping should be regulated—it should—but whether new policies will continue encouraging smokers to switch away from cigarettes or inadvertently make combustible tobacco more competitive.

The debate took centre stage at the UK Vaping Industry Association’s (UKVIA) 2026 Forum in London, where regulators, parliamentarians, manufacturers, retailers and consumer representatives examined how Britain can tackle youth vaping and illicit products without undermining one of its most successful smoking reduction tools.

New duty could spell disaster

The most immediate change arrives on 1 October 2026 with the introduction of the UK’s Vaping Products Duty. Every 10ml bottle of e-liquid—whether it contains nicotine or not—will attract a flat-rate £2.20 excise duty, with VAT added on top. At the same time, manufacturers and importers must introduce digital tax stamps on qualifying products, enabling HM Revenue & Customs to monitor products throughout the supply chain.

Supporters argue that the measures will help reduce youth access while generating an estimated £525 million in revenue. However, many within the vaping sector fear unintended consequences.

Unlike the original proposal for nicotine-based tax bands, the flat-rate model taxes all liquids equally regardless of nicotine strength. Heavy users of lower-strength refillable liquids may therefore pay more than consumers using smaller quantities of higher-strength products.

The broader concern is whether higher prices narrow the financial advantage vaping currently holds over smoking. Multiple international economic studies have shown that cigarettes and vaping products can act as substitute goods. When vaping becomes substantially more expensive, some smokers postpone switching while some former smokers relapse. The latest Cochrane living review continues to find that nicotine e-cigarettes help more adults stop smoking than conventional nicotine replacement therapy, suggesting that maintaining affordability remains an important component of tobacco harm reduction.

Flavours seem next on the list

Alongside taxation, flavour regulation has become one of the most contested issues in UK tobacco policy. The government has launched a consultation proposing restrictions on packaging, branding and colours, simplified flavour descriptions and keeping vaping products out of sight in shops. Yet while protecting children from nicotine use remains a legitimate public health objective, the evidence increasingly suggests policymakers should distinguish between youth-oriented marketing and flavours themselves.

Research presented by UKVIA indicates that non-tobacco flavours remain important for adult smokers trying to distance themselves from cigarettes. Similar findings have emerged from local authority stop-smoking services, where fruit flavours are widely supplied to smokers attempting to quit. This distinction matters.

A flavour description such as “strawberry” simply informs consumers what a product tastes like. Cartoon imagery, confectionery branding or designs clearly intended to appeal to children represent a separate issue and can be regulated independently. Treating every non-tobacco flavour as inherently problematic risks making smoke-free alternatives less appealing to adults, without necessarily reducing youth experimentation.

Specialist vape shops? Totally underrated

The regulatory challenges extend beyond products themselves.

Recent government statements suggesting that relief for businesses “that do not make a positive contribution to local communities, such as vape shops” should be reviewed have generated strong criticism from harm reduction advocates.

The implication that specialist vape retailers contribute little to society sits uneasily alongside evidence that millions of former smokers rely on these businesses for advice, product selection and ongoing support.

Unlike convenience stores, specialist vape shops employ trained staff capable of helping smokers choose appropriate devices, nicotine strengths and refillable systems. Many consumers credit these retailers with helping them remain smoke-free after multiple unsuccessful quit attempts. While smoking still kills approximately half of long-term smokers, the contribution made by specialist retailers cannot easily be dismissed.

Licensing goes hand in hand with enforcement

Rather than targeting legitimate businesses, many industry representatives favour a comprehensive licensing system.

UKVIA and several retailers have proposed licensing manufacturers, distributors and retailers, with licence fees funding Trading Standards enforcement against illegal sellers.

The Tobacco and Vapes Act already provides powers for retail licensing in much of the UK. If implemented effectively, licensing could improve market oversight while allowing regulators to suspend businesses repeatedly found selling to minors or distributing non-compliant products.

Digital tax stamps introduced alongside the Vaping Products Duty could reinforce this approach by making legal supply chains easier to trace. However, licensing will only succeed if enforcement focuses on illicit operators rather than imposing additional administrative burdens on compliant retailers.

Plain packaging risks sending the wrong message

Among the most controversial proposals are plans requiring vaping products to adopt plain packaging and drab colours similar to tobacco products. The intention is clear: reduce youth appeal.

The difficulty is that packaging performs several functions beyond marketing. For adult smokers considering switching, product appearance, brand recognition and clear information help distinguish legitimate products from counterfeit alternatives. Removing these features may unintentionally reinforce the misconception that vaping carries risks comparable to smoking.

Public perception is already moving in the wrong direction.

Recent surveys consistently show that many adults now believe vaping is as harmful as—or even more harmful than—combustible cigarettes despite repeated evidence reviews by Public Health England, the Office for Health Improvement and Disparities and the Royal College of Physicians concluding that vaping is substantially less harmful than smoking. If regulation further blurs this distinction, fewer smokers may see value in switching.

A defining moment for UK tobacco harm reduction

The UK has long been regarded as one of the world’s most progressive countries on tobacco harm reduction. Programmes such as Swap to Stop, widespread integration of vaping into Stop Smoking Services and evidence-based public health messaging have helped accelerate declines in smoking prevalence. The next phase of regulation will determine whether that progress continues.

Children should not vape. Illegal products should be removed from the market. Manufacturers should meet rigorous product standards, while retailers should verify age and comply with environmental obligations. Yet regulation must also preserve the accessibility, affordability and attractiveness of lower-risk alternatives for adults who would otherwise smoke.

Success should not be measured by declining vape sales alone.

Instead, policymakers should ask a more important question: are fewer people smoking as a result? If the answer remains yes, regulation will have achieved its purpose. If tighter restrictions simply make cigarettes relatively more attractive or push consumers into illicit markets, Britain risks weakening one of its most effective public health interventions.

The challenge facing policymakers is therefore not whether to regulate vaping, but how to do so without losing sight of the ultimate objective: replacing combustible cigarettes with substantially lower-risk alternatives and continuing to reduce the enormous burden of smoking-related disease.

Can the UK Britain Tackle Illicit Vapes Without Hurting Adult Smokers Trying to Quit?

Source link

Europe Medical Cannabis Market Surges Amid Regulatory Reforms

admin — Tue, 20 Jan 2026 14:29:30 +0000

The European medical cannabis sector is experiencing unprecedented growth, driven by progressive legislation, expanding patient access, and a maturing supply chain, according to a new report.

Findings from The European Cannabis Report: 10th Edition, published today (Tuesday 29 July), reflect a decade of immense change across European cannabis markets — from early medical pilot programs to the emergence of adult-use frameworks in countries like Germany and Malta.

Germany continues to lead the European medical cannabis market, now valued at over €670 million, thanks to the transformative MedCanG law enacted in April 2024. By removing cannabis from the narcotics list and eliminating bureaucratic hurdles, Germany has created Europe’s most open medical cannabis ecosystem. The market is now supported by over 20 telemedicine clinics, a robust import and distribution network, and falling flower prices, further boosting accessibility.

The Czech Republic and Denmark are establishing themselves as rising European exporters. Czech reforms have enabled commercial cultivation and a significant increase in exports – over 1,300 kg of medical cannabis was shipped to Germany in 2024. In Denmark, a decision to make its pilot programme permanent has cemented the country’s role as a major exporter, with over 7 tonnes sent to Germany in 2024 alone.

Poland is now Europe’s fourth-largest market, projected at €72 million in 2025. Recent regulatory improvements, product approvals, and telemedicine adoption spurred rapid growth, although a 2024 ban on online-first consultations has introduced new friction.

In the UK, the medical cannabis market—entirely private—is expected to exceed €300 million in 2025. Over 30 telehealth platforms serve a rapidly expanding patient base, although high treatment prices and a lack of public reimbursement remain key challenges. Domestic production is ramping up, with several UK-based producers now supplying locally cultivated cannabis.

“The UK medical cannabis market is entering a new phase—defined by scale, sophistication, and strong signals of long-term viability,” said Lawrence Purkiss, senior analyst at Prohibition Partners. “As domestic cultivation scales and digital access becomes more embedded, the market is evolving rapidly from niche to mainstream—creating opportunity for global players and local pioneers alike.”

Meanwhile, Italy remains tightly regulated, with state-controlled cultivation and procurement largely restricting market growth. Despite being one of the first movers in Europe, the market remains dominated by a few suppliers, led by Bedrocan.

Across the continent, flowers remain the dominant product format, but oils, extracts, and even vape cartridges are gaining traction—especially in markets like Germany and the UK. Canadian, Portuguese, and Danish producers continue to dominate exports into the region.

As Europe edges closer to harmonised frameworks and broader patient access, the medical cannabis sector is poised for continued acceleration, potentially surpassing €1.5 billion in combined value across leading markets by the end of the decade.

The 10th edition of the European Cannabis Report, long regarded as the go-to European resource for investors, regulators, operators, and policymakers across the global cannabis landscape, is now available to view via Prohibition Partners’ Insights Hub, a dynamic new digital platform unveiled today, that transforms traditional industry reporting into a live, continuously evolving intelligence experience.

“Since 2017, we’ve been charting the evolution of cannabis markets across Europe, we knew it was time for something new that matched the pace, scale, and complexity of what’s happening on the ground,” Prohibition Partners CEO, Stephen Murphy, explained.

“This isn’t just a new edition of our report—it’s a complete reimagining of how we deliver insights and data. The Insights Hub gives businesses, policymakers, and patients real-time access to the data and analysis they need to navigate an industry that is no longer changing year by year, but week by week.”

Prohibition Partners’ Insights Hub is now live and available to access for free. To access and explore, visit: insightshub.prohibitionpartners.com

Source link